Docket Room
SB 465·NH·senate

classifying xylazine as a schedule III controlled drug.

FailedFiled Nov 21, 2025
Sponsor: Bill Gannon (R)
Latest Action

Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55

Apr 23, 2026

Summary

The bill sought to reclassify xylazine as a Schedule III controlled drug in New Hampshire, changing its legal status. This would affect anyone possessing, distributing, or prescribing the substance by subjecting it to Schedule III regulations. The measure was rejected as “inexpedient to legislate.”

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Share

Track this bill

Get real-time alerts when SB 465 changes status, plus AI-powered summaries and stage predictions.

Sign up free
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice